The cancer that most commonly affects the mouth of cats is called oral squamous cell carcinoma (OSCC). This cancer is common and responds poorly to treatment. The average life expectancy for cats diagnosed with this cancer is approximately six-months. Cats may exhibit a number of problems as a result of OSCC, including a swelling in the head/throat, lack of appetite, difficulty eating or swallowing, decreased grooming behavior, excessive salivation, foul odor of breath, change in voice or difficulty vocalizing. The purpose of this study is to determine if a drug called “Anginex” would provide a safe and effective means of treating OSCC in cats. Anginex is a small protein that interferes with the ability of a tumor to make and maintain its blood supply, a process known as angiogenesis. Cancer drugs that target the blood supply of a tumor are called “anti-angiogenic” agents. Because tumors need a blood supply to grow beyond a microscopic size, inhibiting angiogenesis prevents tumors from growing and can cause tumors to shrink. Anginex has been used in mice experimentally. We have also performed a pilot study in cats with OSCC. The current clinical study in which we are enrolling cats investigates Amginex’s effectiveness on the tumor and its blood vessels and oxygen levels.
For more information regarding this study please visit: http://sites.tufts.edu/vetclinicaltrials/